Marksans Pharma · NSE: MARKSANS · BSE: 524404
Q2 FY24 results · Jul–Sep 2023
Marksans Pharma reported revenue from operations of ₹531.24 crore (up 17.4% from Q2 FY23) and net profit of ₹83.85 crore (up 39.5% from Q2 FY23) for Q2 FY24 (Jul–Sep 2023), on a consolidated basis.
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 531.24 | 452.56 | +17.4% | 500.03 | +6.2% |
| Other income | 19.00 | 14.15 | +34.2% | 10.10 | +88.2% |
| Total income | 550.23 | 466.72 | +17.9% | 510.13 | +7.9% |
| Profit before tax | 113.77 | 77.83 | +46.2% | 96.83 | +17.5% |
| Net profit for the period | 83.85 | 60.12 | +39.5% | 70.44 | +19.0% |
| Attributable to shareholders of the company | 83.52 | 61.25 | +36.3% | 68.66 | +21.6% |
| EPS, basic (₹) | 1.84 | 1.52 | not comparable | 1.52 | +21.1% |
| Net margin (%) | 15.8 | 13.3 | 14.1 |
| Item | Q2 FY24 | Q2 FY23 | YoY | Q1 FY24 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 204.67 | 170.26 | +20.2% | 182.04 | +12.4% |
| Other income | 15.93 | 21.03 | −24.3% | 32.62 | −51.2% |
| Total income | 220.60 | 191.29 | +15.3% | 214.66 | +2.8% |
| Profit before tax | 44.50 | 48.98 | −9.2% | 54.40 | −18.2% |
| Net profit for the period | 31.29 | 40.23 | −22.2% | 44.19 | −29.2% |
| EPS, basic (₹) | 0.69 | 1.00 | not comparable | 0.98 | −29.6% |
| Net margin (%) | 15.3 | 23.6 | 24.3 |
Consolidated
- Filed with BSE
- 13 Nov 2023, 15:08 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 13 Nov 2023, 15:08 IST
- Board meeting
- 09 Nov 2023
- Period
- 01 Jul 2023 to 30 Sep 2023
- Review status
- Unaudited
- Source
- XBRL filing on BSE